Profile
| Metric | Value |
|---|---|
| Full Name | United Therapeutics Corporation |
| Ticker | NASDAQ: UTHR |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | unither.com |
| Employees | 1,305 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $503.95 | |
| Price, 1D Change | +2.91% | |
| Market Cap | $22B | |
| - | ||
| PE Ratio | 19.10 | |
| Beta | 0.38 | |
| Revenue | $3B | |
| Revenue, 1Y Change | +23.63% | |
| EPS | $24.64 | |
| EPS, 1Y Change | +24.36% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $24.64 | |
| EPS Estimate | $27.10 | |
| EPS Est. Change | +9.97% | |
| Revenue | $2.88B | |
| Revenue Estimate | $3.21B | |
| Revenue Est. Change | +11.39% | |
| Current Price | $503.95 | |
| Price Target | - | $525.00 |
| Price Tgt. Change | - | +4.18% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $19.61 | $19.81 | +1.04% | |
| $24.57 | $24.64 | +0.30% | |
| $27.10 | N/A | +9.97% | |
| $28.64 | N/A | +16.21% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.29B | $2.33B | +1.57% | |
| $2.88B | $2.88B | +0.08% | |
| $3.21B | N/A | +11.39% | |
| $3.39B | N/A | +17.79% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +41.80% | |
| Price, 3Y | +82.48% | |
| Market Cap, 1Y | +36.19% | |
| Market Cap, 3Y | +70.68% | |
| Revenue, 1Y | +23.63% | |
| Revenue, 3Y | +70.71% | |
| EPS, 1Y | +24.36% | |
| EPS, 3Y | +144.96% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $503.95 | |
| SMA 200 | $366.71 | |
| SMA 200 vs Price | -27.23% | |
| SMA 50 | $475.26 | |
| SMA 50 vs Price | -5.69% | |
| Beta | 0.38 | |
| ATR | $12.33 | |
| 14-Day RSI | 48.65 | |
| 10-Day Volatility | 22.43% | |
| 1-Year Volatility | 48.24% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $2.88B | |
| EPS | $24.64 | |
| Gross Profit | $2.57B | |
| Gross Margin | 89.24% | |
| Operating Profit | $1.45B | |
| Operating Margin | 50.33% | |
| Net Income | $1.20B | |
| Net Margin | 41.53% | |
| EBITDA | $1.65B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.05 | |
| Current Ratio | 5.25 | |
| Quick Ratio | 5.03 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 16.05 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 19.10 | |
| PS Ratio | 6.94 | |
| PB Ratio | 3.29 | |
| EV/EBITDA | 11.84 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $6.44B | |
| Cash & Equivalents | $1.70B | |
| Total Assets | $7.44B | |
| Current Assets | $3.87B | |
| Total Liabilities | $994.40M | |
| Current Liabilities | $738.10M | |
| Total Debt | $300.00M | |
| Short Term Debt | $300.00M | |
| Accounts Payable | $6.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.43B | |
| Operating Expenses | $1.12B | |
| Cost Of Goods Sold | $309.70M | |
| SG&A | $638.60M | |
| D&A | $72.50M | |
| Interest Expense | $0.00 | |
| Income Tax | $343.90M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $1.33B | |
| CFI | $417.20M | |
| CFF | -$1.25B | |
| Capex | $246.50M | |
| Free Cash Flow | $1.08B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| UBS | → | |
| Wells Fargo | → | |
| RBC Capital | → | |
| HC Wainwright & Co. | → | |
| Morgan Stanley | → | |
| UBS | → | |
| RBC Capital | ||
| Cantor Fitzgerald | → | |
| Oppenheimer | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with UTHR
Data Sources & References
- UTHR Official Website www.unither.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1082554/000108255425000034/0001082554-25-000034-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1082554/000108255425000005/0001082554-25-000005-index.htm
- UTHR Profile on Yahoo Finance finance.yahoo.com/quote/UTHR
- UTHR Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/uthr
FAQ
What is the ticker symbol for United Therapeutics Corporation?
The ticker symbol for United Therapeutics Corporation is NASDAQ:UTHR
Does United Therapeutics Corporation pay dividends?
No, United Therapeutics Corporation does not pay dividends
What sector is United Therapeutics Corporation in?
United Therapeutics Corporation is in the Healthcare sector
What industry is United Therapeutics Corporation in?
United Therapeutics Corporation is in the Specialty & Generic Drug Manufacturers industry
What country is United Therapeutics Corporation based in?
United Therapeutics Corporation is headquartered in United States
When did United Therapeutics Corporation go public?
United Therapeutics Corporation initial public offering (IPO) was on June 17, 1999
Is United Therapeutics Corporation in the S&P 500?
No, United Therapeutics Corporation is not included in the S&P 500 index
Is United Therapeutics Corporation in the NASDAQ 100?
No, United Therapeutics Corporation is not included in the NASDAQ 100 index
Is United Therapeutics Corporation in the Dow Jones?
No, United Therapeutics Corporation is not included in the Dow Jones index
When was United Therapeutics Corporation last earnings report?
United Therapeutics Corporation's most recent earnings report was on October 29, 2025
When does United Therapeutics Corporation report earnings?
The next expected earnings date for United Therapeutics Corporation is February 25, 2026
